

REMARKS

Amendments

Claims 1, 5-6, and 23-27 have been cancelled.

Claims 13 and 14 have been amended to be rewritten in independent form.

Claims 20-22 have been amended to properly recite, “The mammalian cell line of”, and depend from claim 11. Support for these amendments can be found, for example, at paragraphs 17 and 28 and under the Sequence Listing in the Specification.

Rejection Under 35 U.S.C. § 112

The Examiner rejected claims 1, 5, 6, 23-25 and 27 under 35 U.S.C. § 112, first paragraph, as failing to comply with the written description requirement. The Examiner’s rejection of claims 1, 5, 6, 23-25 and 27 has been rendered moot by cancellation of those claims.

The Examiner rejected claims 20-22 as being indefinite due to a lack of antecedent basis for “The expression cassette of claim 15(16).” Applicants have amended the claims to properly recite, “The mammalian cell line of”, and depend from claim 11. Withdrawal of this rejection is requested.

Allowable Subject Matter

Claims 11, 12, 15 and 16 have been allowed.

The Examiner indicated claims 13 and 14 would be allowable if rewritten in independent form including all of the limitations of the base claim and any intervening claims. Applicant has amended claims 13 and 14 to be rewritten in independent form, and thus claims 13 and 14 are allowable. Claims 17-19 each are allowable as a claim depending from an allowable claim.

Conclusion

In view of the above amendment and remarks, it is submitted that the claims satisfy the requirements of the patent statutes and are patentable over the prior art of record. Reconsideration of this application and early notice of allowance is requested. The Examiner is invited to telephone

Application Serial No. 10/629,895
Amendment dated 11 April 2011
Reply to Office Action dated 25 January 2011

the undersigned if it will assist in expediting the prosecution and allowance of the instant application.

Respectfully submitted,

ROTHWELL, FIGG, ERNST & MANBECK, p.c.

By /Jeffrey L. Ihnen/

Jeffrey L. Ihnen

Registration No. 28,957

1425 K Street, N.W., Suite 800

Washington, D.C. 20005

Telephone No.: (202) 783-6040

Facsimile No.: (202) 783-6031